The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells
Open accessAbstract
Background & aims Several studies have shown that development of hepatocellular carcinoma (HCC) generates a number of immune suppressive mechanisms in these patients. Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of cells that have been shown to inhibit T-cell responses in tumor-bearing mice, but little is known about these cells in humans owing to a lack of specific markers. In this study, we have investigated the frequency and function of a new population of MDSC denoted here as CD14(+)HLA-DR(-/low) in HCC patients. We have also identified a novel, MDSC-mediated immune regulatory pathway in these patients.Methods We have directly isolated and characterized MDSCs for phenotype and function from peripheral blood (n = 111) and tumor (n = 12) of patients with HCC.Results The frequency of CD14(+)HLA-DR(-/low) cells in peripheral blood mononuclear cells (PBMC) from HCC patients was significantly increased in comparison with healthy controls. CD14(+) HLA-DR(-/low) cells were unable to stimulate an allogeneic T-cell response, suppressed autologous T-cell proliferation, and had high arginase activity, a hallmark characteristic of MDSC. Most important, CD14(+)HLA-DR(-/low) cells from HCC patients induced a CD4(+)CD25(+)Foxp3(+) regulatory T-cell population when cocultured with autologous T cells.Conclusion CD14(+)HLA-DR(-/low) cells are a new population of MDSC increased in blood and tumor of HCC patients. We propose a new mechanism by which MDSC exert their immunosuppressive function, through the induction of CD4(+)CD25(+)Foxp3(+) regulatory T cells in cocultured CD4(+) T cells. Understanding the mechanism of action of MDSC in HCC patients is important in the design of effective immunotherapeutic protocols.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The liver also contains an abundance of MDSCs that produce factors suppressing T cell activation63.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [63]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature reviews. Immunology · doi:10.1038/nri1806 · Cited by 2,135
Jonuleit, H., Schmitt, E., Schuler, G., Knop, J., & Enk, A. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.9.1213 · Cited by 1,538
Swann, J. B., & Smyth, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31405 · Cited by 1,518
Huang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,340
Rodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0465 · Cited by 1,276
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
Nagaraj, S., Gupta, K., Писарев, В. М., Kinarsky, L., Sherman, S., Kang, L., Herber, D. L., Schneck, J. P., & Gabrilovich, D. I. (2007) · Nature Medicine · doi:10.1038/nm1609 · Cited by 1,176
Gao, Q., Qiu, S., Fan, J., Zhou, J., Wang, X., Xiao, Y., Xu, Y., Li, Y., & Tang, Z. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4565 · Cited by 1,134
Schmielau, J., & Finn, O. J. (2001) · PubMed · Cited by 867
Cited by
Sorted by citations
Items 401–500 of 790
Nishida, N., & Kudo, M. (2020) · Cancers · doi:10.3390/cancers12051274 · Cited by 36
Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
Chandrasekaran, S., Funk, C. R., Kleber, T. J., Paulos, C. M., Shanmugam, M., & Waller, E. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.718621 · Cited by 36
Sun, S. H., Benner, B. N., Savardekar, H., Lapurga, G., Good, L., Abood, D., Nagle, E., Duggan, M. C., Stiff, A. R., DiVincenzo, M. J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.740890 · Cited by 36
Klein, O., Davis, I. D., McArthur, G. A., Chen, L., Haydon, A. M., Parente, P., Dimopoulos, N., Jackson, H. M., Xiao, K., Maraskovsky, E., et al. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1656-x · Cited by 37
Soler, D. C., Young, A. B., Fiessinger, L., Galimberti, F., Debanne, S. M., Groft, S. G., McCormick, T. S., & Cooper, K. D. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2015.12.036 · Cited by 36
Development of an Insert Co-culture System of Two Cellular Types in the Absence of Cell-Cell Contact
Renaud, J., & Martinoli, M. (2016) · Journal of Visualized Experiments · doi:10.3791/54356 · Cited by 35
Diaz-Montero, C. M., Wang, Y., Shao, L., Feng, W., Zidan, A. A., Pazoles, C. J., Montero, A. J., & Zhou, D. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.02.007 · Cited by 35
Myeloid-derived suppressor cells in lymphoma: The good, the bad and the ugly
Betsch, A., Rutgeerts, O., Fevery, S., Sprangers, B., Verhoef, G. E. G., Dierickx, D., & Beckers, M. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.04.006 · Cited by 35
Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma
Tomimaru, Y., Mishra, S., Safran, H. P., Charpentier, K. P., Martin, W. D., Groot, A. S. D., Gregory, S. H., & Wands, J. R. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.01.037 · Cited by 34
Mkrtichyan, M., Ghochikyan, A., Davtyan, H., Movsesyan, N., Loukinov, D., Lobanenkov, V. V., Cribbs, D. H., Laust, A. K., Nelson, E. L., & Agadjanyan, M. G. (2011) · Cellular Immunology · doi:10.1016/j.cellimm.2011.05.007 · Cited by 34
Li, X., Peng, J., Pang, Y., Yu, S., Yu, X., Chen, P., Wang, W., Han, W., Zhang, J., Yin, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep14757 · Cited by 34
Immune microenvironment and immunotherapy in hepatocellular carcinoma: mechanisms and advances
Xie, D., Liu, Y., Xu, F., Dang, Z., Li, M., Zhang, Q., & Dang, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1581098 · Cited by 35
Zhu, J., Feng, A., Sun, J., Jiang, Z.-Z., Zhang, G., Wang, K., Hu, S., & Qu, X. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06765.x · Cited by 33
Role of Myeloid-Derived Suppressor Cells in Tumor Immunotherapy
Martin, F., Apétoh, L., & Ghiringhelli, F. (2011) · Immunotherapy · doi:10.2217/imt.11.154 · Cited by 33
Potentiality of immunotherapy against hepatocellular carcinoma
Tsuchiya, N. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i36.10314 · Cited by 33
Insights Into Mechanisms of Tumor and Immune System Interaction: Association With Wound Healing
Ponomarev, А. V., & Shubina, I. Z. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01115 · Cited by 36
Alabanza, L. M., Esmon, N. L., Esmon, C. T., & Bynoe, M. S. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202556 · Cited by 34
Yin, J., Wang, C., Huang, M., Mao, X., Zhou, J., & Zhang, Y. (2016) · Cancer Medicine · doi:10.1002/cam4.688 · Cited by 33
Wang, C., Zhang, N., Qi, L., Yuan, J., Wang, K., Wang, K., Ma, S., Wang, H., Lou, W., Hu, P., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700671 · Cited by 33
The Immune System in Hepatocellular Carcinoma and Potential New Immunotherapeutic Strategies
Bertino, G., Demma, S., Ardiri, A., Proiti, M., Malaguarnera, G., Bertino, N., Malaguarnera, M., & Malaguarnera, M. (2015) · BioMed Research International · doi:10.1155/2015/731469 · Cited by 32
RetractedOkła, K., Wertel, I., Polak, G., Surówka, J., Wawruszak, A., & Kotarski, J. (2016) · International Reviews of Immunology · doi:10.1080/08830185.2016.1206097 · Cited by 35
Takahashi, H., Sakakura, K., Tada, H., Kaira, K., Oyama, T., & Chikamatsu, K. (2019) · Head & Neck · doi:10.1002/hed.25625 · Cited by 32
Wen, Q.-X., Han, T., Wang, Z., & Jiang, S. (2020) · Oncology Letters · doi:10.3892/ol.2020.11369 · Cited by 32
Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
Zhong, C. F., Li, Y., Yang, J., Jin, S., Chen, G., Li, D., Fan, X., & Lin, H. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.589680 · Cited by 32
Therapeutic Values of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma: Facts and Hopes
Wang, Y., Zhang, T., Sun, M., Ji, X., Xie, M., Huang, W., & Xia, L. (2021) · Cancers · doi:10.3390/cancers13205127 · Cited by 34
Vogt, A., Sievers, E., Lukacs‐Kornek, V., Decker, G., Raskopf, E., Meumann, N., Büning, H., Sauerbruch, T., Strassburg, C. P., Schmidt‐Wolf, I. G. H., et al. (2013) · Liver International · doi:10.1111/liv.12284 · Cited by 32
Pang, X., Song, H., Zhang, Q., Tu, Z., & Niu, J. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.01.014 · Cited by 32
Lentiviral Vectors: A Versatile Tool to Fight Cancer
Emeagi, P. U., Goyvaerts, C., Maenhout, S. K., Pen, J. J., Thielemans, K., & Breckpot, K. (2013) · Current Molecular Medicine · doi:10.2174/1566524011313040011 · Cited by 31
Tolerogenic Role of Myeloid Suppressor Cells in Organ Transplantation
Ochando, J., Conde, P., Utrero‐Rico, A., & Paz‐Artal, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00374 · Cited by 32
Papadakos, S. P., Arvanitakis, K., Stergiou, I. Ε., Lekakis, V., Davakis, S., Christodoulou, M., Germanidis, G. S., & Theocharis, S. E. (2023) · Cancers · doi:10.3390/cancers15102795 · Cited by 31
Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications
Fatourou, E. M., & Koskinas, J. S. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.103 · Cited by 30
Zhou, Z., Hu, Y., Wu, Y., Qi, Q., Wang, J., Chen, L., & Wang, F. (2022) · Molecular Immunology · doi:10.1016/j.molimm.2022.09.010 · Cited by 31
Regulatory T Cells in Colorectal Cancer: From Biology to Prognostic Relevance
Mougiakakos, D. (2011) · Cancers · doi:10.3390/cancers3021708 · Cited by 30
Ilkovitch, D., & Ferris, L. K. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5685 · Cited by 30
Liposomal clodronate treatment for tumour macrophage depletion in dogs with soft‐tissue sarcoma
Guth, A., Hafeman, S., Elmslie, R. E., & DOW, S. W. (2012) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2012.00319.x · Cited by 30
Harding, J. J. (2018) · Future Oncology · doi:10.2217/fon-2018-0008 · Cited by 30
Anti-stromal nanotherapeutics for hepatocellular carcinoma
Yu, Z., Huang, L., & Guo, J. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.050 · Cited by 30
Tazzari, M., Negri, T., Rini, F., Vergani, B., Huber, V., Villa, A., Dagrada, G. P., Colombo, C., Fiore, M., Gronchi, A., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.437 · Cited by 29
Regulatory T cells in gastrointestinal tumors
Raghavan, S., & Quiding‐Järbrink, M. (2011) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.11.44 · Cited by 29
Matsunaga, T., Saito, H., & Ikeguchi, M. (2011) · Europe PMC (PubMed Central) · Cited by 29
Heine, A., Flores, C., Gevensleben, H., Diehl, L., Heikenwälder, M. F., Ringelhan, M., Janssen, K., Nitsche, U., Garbi, N., Brossart, P., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1338995 · Cited by 29
Liu, Y., Kim, E. S., & Guo, H. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29485 · Cited by 28
Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives
Rajkumari, S., Singh, J., Agrawal, U., & Agrawal, S. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112949 · Cited by 28
Remodeling the tumor dormancy ecosystem to prevent recurrence and metastasis
Liang, Y., Chen, W., Zhang, Y., & Li, L. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02328-2 · Cited by 29
Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment
Heuvers, M. E., Aerts, J. G. J. V., Cornelissen, R., Groen, H. J. M., Hoogsteden, H. C., & Hegmans, J. P. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-580 · Cited by 28
Macrophage NOS2 in Tumor Leukocytes
Brüne, B., Courtial, N., Dehne, N., Syed, S. N., & Weigert, A. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6811 · Cited by 28
Bing, X., Yang, M., Wu, P., Du, L., Deng, X., Hui, E., & Feng, G. (2021) · Hepatology · doi:10.1002/hep.32266 · Cited by 28
Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy
Feng, H., Zhuo, Y., Zhang, X., Li, Y., Li, Y., Duan, X., Shi, J., Xu, C., Gao, Y., & Yu, Z. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s381764 · Cited by 29
The Role of Chemokines in Hepatitis C Virus-Mediated Liver Disease
Braß, A., & Brenndörfer, E. D. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15034747 · Cited by 29
Expansion of Myeloid-Derived Suppressor Cells in Patients with Acute Coronary Syndrome
Wang, Y., Xiong, X., Chen, Z.-Y., Liu, K.-L., Yang, J., Wen, Q., Wu, F., Hu, X.-F., Peng, Y., Wu, J., et al. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000369696 · Cited by 28
Myeloid-derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in cancer
Li, L., Li, M., & Jia, Q. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154711 · Cited by 28
The immunosuppressive role of MDSCs in HCC: mechanisms and therapeutic opportunities
Liu, X., Kang, X., Kang, H., & Yan, H. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02170-7 · Cited by 29
Cross-Talk between Tumor and Myeloid Cells: How to Tip the Balance in Favor of Antitumor Immunity
Lindenberg, J. J., Fehres, C. M., van Cruijsen, H., Oosterhoff, D., & de Gruijl, T. D. (2010) · Immunotherapy · doi:10.2217/imt.10.95 · Cited by 27
Myeloid-Derived Suppressor Cells: Facilitators of Cancer and Obesity-Induced Cancer
Ostrand‐Rosenberg, S. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-042120-105240 · Cited by 27
Targeting ferroptosis in hepatocellular carcinoma
Mo, Y., Zou, Z., & Chen, E. (2023) · Hepatology International · doi:10.1007/s12072-023-10593-y · Cited by 29
Immunosuppressive CD11b+Ly6Chi monocytes in pristane-induced lupus mouse model
Ma, H., Wan, S., & Xia, C. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a0415-158r · Cited by 27
Cappello, P., Tonoli, E., Curto, R., Giordano, D., Giovarelli, M., & Novelli, F. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1112940 · Cited by 26
Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma
Zhu, Y., & Qin, L. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.08.003 · Cited by 26
Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
Liu, J., Tao, H., Yuan, T., Li, J., Li, J., Liang, H., Huang, Z., & Zhang, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.992611 · Cited by 27
The role of myeloid-derived suppressor cells in liver cancer
Zhou, S., Zhao, Z., Zhong, H., Ren, Z., Li, Y., Wang, H., & Qiu, Y. (2023) · Discover Oncology · doi:10.1007/s12672-023-00681-8 · Cited by 26
Frontline therapy for advanced hepatocellular carcinoma: an update
Akce, M., El‐Rayes, B. F., & Bekaii‐Saab, T. (2022) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848221086126 · Cited by 26
The role of immune regulation in HBV infection and hepatocellular carcinogenesis
Zheng, H., Xu, B., Fan, Y., Tuekprakhon, A., Stamataki, Z., & Wang, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1506526 · Cited by 26
Sui, Y., Frey, B. F., Wang, Y., Billeskov, R., Kulkarni, S., McKinnon, K. M., Rourke, T., Fritts, L., Miller, C. J., & Berzofsky, J. A. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006395 · Cited by 25
Immunotherapy: Current Status and Future Perspectives
Floudas, C. S., Brar, G. S., & Greten, T. F. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05516-7 · Cited by 25
Self-citationYang, Z., Liang, A.-B., & Ansell, S. M. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1011640 · Cited by 25
Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?
Obeid, J. M., Kunk, P. R., Zaydfudim, V. M., Bullock, T. N. J., Slingluff, C. L., & Rahma, O. E. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2082-z · Cited by 25
Lee, W., Wang, Y., Cheng, C., Wu, T., Lee, C., Wu, T.-J., Chou, H., & Chan, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-38785-3 · Cited by 25
Cuenca‐Escalona, J., Subtil, B., Garcia-Perez, A., Cambi, A., de Vries, I. J. M., & Flórez‐Grau, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1355769 · Cited by 24
Ning, G., She, L., Lu, L., Liu, Y., Zeng, Y., Yan, Y., & Lin, C. (2015) · BioMed Research International · doi:10.1155/2015/385378 · Cited by 24
Gao, M., Huang, A., Sun, Z., Sun, Y. H., Chang, B., Zhang, J., & Zou, Z. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14109 · Cited by 24
The spleen contributes to the increase in PMN-MDSCs in orthotopic H22 hepatoma mice
Li, B.-H., Jiang, W., Zhang, S., Huang, N., Sun, J., Yang, J. J., & Li, Z. (2020) · Molecular Immunology · doi:10.1016/j.molimm.2020.07.002 · Cited by 24
Sehgal, R., Maiwall, R., Vijayaraghavan, R., Islam, M., Baweja, S., Kaur, N., Kumar, G., Ramakrishna, G., Sarin, S. K., & Trehanpati, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.828949 · Cited by 24
Al‐Taei, S., Banner, R., Powell, N. G., Evans, M., Palaniappan, N., Tabi, Z., & Man, S. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1488-5 · Cited by 24
Ren, J. P., Wang, L., Zhao, J., Wang, L., Ning, S., Gazzar, M. E., Moorman, J. P., & Yao, Z. Q. (2016) · Immunology · doi:10.1111/imm.12680 · Cited by 24
Natural killer cells involved in tumour immune escape of hepatocellular carcinomar
Chen, H., Jiang, Y., Wang, Z., & Wang, H. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.04.057 · Cited by 25
Guardascione, M., & Toffoli, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176302 · Cited by 24
Chen, H., Lu, D., Yang, X., Hu, Z., He, C., Li, H., Lin, Z., Yang, M., & Xu, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.879552 · Cited by 23
Tumor vaccines in 2010: Need for integration
Koos, D., Josephs, S. F., Alexandrescu, D. T., Chan, R. C., Ramos, F., Bogin, V., Gammill, V., Dasanu, C. A., de Necochea-Campion, R., Riordan, N. H., et al. (2010) · Cellular Immunology · doi:10.1016/j.cellimm.2010.03.019 · Cited by 23
CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma
Cubillos‐Zapata, C., Córdoba, R., Ortiz, J. A., Arribas-Jiménez, C., Hernández-Jiménez, E., Toledano, V., Villaescusa, T., Moreno, V., & López‐Collazo, E. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1231290 · Cited by 23
The Promise of Immunotherapy in the Treatment of Hepatocellular Carcinoma
El-Khoueiry, A. B. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175230 · Cited by 25
Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma
Gao, X. Y., & McDermott, D. F. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000323 · Cited by 23
Tazzari, M., Palassini, E., Vergani, B., Villa, A., Rini, F., Negri, T., Colombo, C., Crippa, F., Morosi, C., Casali, P. G., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1044-0 · Cited by 23
Tella, S. H., Mahipal, A., Kommalapati, A., & Jin, Z. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s214870 · Cited by 22
Immunobiology of hepatocellular carcinoma
Flecken, T., Spangenberg, H. C., & Thimme, R. (2011) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-011-0783-x · Cited by 22
Human Th17 cells in patients with cancer
Greten, T. F., Zhao, F., Gamrekelashvili, J., & Korangy, F. (2012) · OncoImmunology · doi:10.4161/onci.21245 · Cited by 22
Self-citationKuroda, H., Saito, H., & Ikeguchi, M. (2012) · Gastric Cancer · doi:10.1007/s10120-011-0138-x · Cited by 22
IFN-γ differentially regulates subsets of Gr-1+CD11b+ myeloid cells in chronic inflammation
Zhan, X., Fang, Y., Hu, S., Wu, Y., Yang, K., Liao, C., Zhang, Y., Huang, X., & Wu, M. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.05.011 · Cited by 22
Resheq, Y. J., Li, K., Ward, S., Wilhelm, A., Garg, A., Curbishley, S. M., Blahova, M., Zimmermann, H. W., Jitschin, R., Mougiakakos, D., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401046 · Cited by 23
Xi, Q., Li, Y., Dai, J., & Chen, W. (2015) · Immunological Investigations · doi:10.3109/08820139.2014.999937 · Cited by 22
Désert, R., Giannone, F., Saviano, A., Hoshida, Y., Heikenwälder, M. F., Nahon, P., & Baumert, T. F. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00018-y · Cited by 23
Myeloid-derived suppressor cells (MDSC): Another player in the orchestra
Gimeno, R., & Barquinero, J. (2011) · Inmunología · doi:10.1016/s0213-9626(11)70015-4 · Cited by 21
Correlation between myeloid-derived suppressor cells and S100A8/A9 in tumor and autoimmune diseases
Zheng, R., Chen, S., & Chen, S. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.10.014 · Cited by 21
Repáraz, D., Aparicio, B., Llópiz, D., Hervás‐Stubbs, S., & Sarobe, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042022 · Cited by 24
Chen, M., Chen, P., Hsieh, C., & Wang, C. (2023) · Cells · doi:10.3390/cells12020332 · Cited by 21
Heftrig, D., Sturm, R., Oppermann, E., Kontradowitz, K., Jurida, K., Schimunek, L., Woschek, M., Marzi, İ., & Relja, B. (2017) · Mediators of Inflammation · doi:10.1155/2017/2608349 · Cited by 21
Mukherjee, S., Ghosh, S., Sengupta, A., Sarkar, S., Keswani, T., Chatterjee, R., & Bhattacharyya, A. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155910 · Cited by 21
Myeloid-derived suppressor cells in cancer
Gao, J., Liu, W., Tang, Z., Fan, J., & Shi, Y. (2022) · iLiver · doi:10.1016/j.iliver.2022.06.002 · Cited by 21
Stromal-dependent tumor promotion by MIF family members
Mitchell, R. A., & Yaddanapudi, K. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.09.012 · Cited by 21
Extracorporeal photochemotherapy induces arginase 1 in patients with graft versus host disease
Merlin, É., Gonçalves-Mendes, N., Hannani, D., de la Torre, A., Farges, M. ‐., Laroye, H., Deméocq, F., Kanold, J., & Vasson, M. (2010) · Transplant Immunology · doi:10.1016/j.trim.2010.10.007 · Cited by 20
Cell-mediated immune responses to α-fetoprotein and other antigens in hepatocellular carcinoma
Behboudi, S., Boswell, S., & Williams, R. L. (2009) · Liver International · doi:10.1111/j.1478-3231.2009.02194.x · Cited by 20
Metadata
- Authors
- Hoechst, B., Ormandy, L. A., Ballmaier, M., Lehner, F., Krüger, C., Manns, M. P., Greten, T. F., & Korangy, F.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- Corresponding author
- Korangy, Firouzeh
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2008-07
- Volume
- 135
- Issue
- 1
- Pages
- 234-243
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2059688175
- Cited by
- 793
- References
- 31
- Citations by year
- 2026: 18 · 2025: 20 · 2024: 25 · 2023: 34 · 2022: 50 · 2021: 46 · 2020: 53 · 2019: 40 · 2018: 39 · 2017: 60 · 2016: 54 · 2015: 65 · 2014: 55 · 2013: 65 · 2012: 59
- FWCI
- 15.02
- Type
- journal article
- Language
- en
- Update notices
- erratum (2011-08-01)
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (SFB-738)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- myeloid-derived suppressor cells, hepatocellular carcinoma, regulatory T cells, immunosuppression, arginase activity, CD4+CD25+Foxp3+ T cells, tumor immune microenvironment, T cell proliferation inhibition, cancer immunotherapy
- MeSH terms
- Aged, Arginase, Cell Communication, Cell Division, Cells, Cultured, Female, Flow Cytometry, Carcinoma, Hepatocellular, HLA-DR Antigens, Humans, Immune Tolerance, Liver Neoplasms, Male, Middle Aged, Biomarkers, CD4-Positive T-Lymphocytes, CD4 Antigens, Immunophenotyping, Interleukin-10, Lipopolysaccharide Receptors, Myeloid Cells, Forkhead Transcription Factors, Interleukin-2 Receptor alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
